Propanc Biopharma, Inc. FY 2026: Revenue $0 EPS $(17.62) — 10-K Summary

Propanc Biopharma, Inc. reported fiscal 2026 results as a development-stage company, with no revenue and a reduced net loss versus the prior year. Revenue was $0 in both FY 2026 and FY 2025, and the net loss available to common stockholders narrowed to $(19.79M) for FY 2026 from $(58.92M) in FY 202…